Pretargeting for imaging and therapy in oncological nuclear medicine
Abstract Background Oncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achieved market approval even though it could be considered the ultimate th...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2017-06-01
|
| Series: | EJNMMI Radiopharmacy and Chemistry |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s41181-017-0026-8 |
| _version_ | 1818590558264754176 |
|---|---|
| author | Clément Bailly Caroline Bodet-Milin Caroline Rousseau Alain Faivre-Chauvet Françoise Kraeber-Bodéré Jacques Barbet |
| author_facet | Clément Bailly Caroline Bodet-Milin Caroline Rousseau Alain Faivre-Chauvet Françoise Kraeber-Bodéré Jacques Barbet |
| author_sort | Clément Bailly |
| collection | DOAJ |
| description | Abstract Background Oncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achieved market approval even though it could be considered the ultimate theranostic, combining PET imaging with short-lived positron emitters and therapy with radionuclides emitting beta or alpha particles. Results We have reviewed the pretargeting approaches proposed over the years, discussing their suitability for imaging, particularly PET imaging, and therapy, as well as their limitations. The reviewed pretargeting modalities are the avidin-biotin system, bispecific anti-tumour x anti-hapten antibodies and bivalent haptens, antibody-oligonucleotide conjugates and radiolabelled complementary oligonucleotides, and approaches using click chemistry. Finally, we discuss recent developments, such as the use of small binding proteins for pretargeting that may offer new perspectives to cancer pretargeting. Conclusions While pretargeting has shown promise and demonstrated preclinical and clinical proof of principle, full-scale clinical development programs are needed to translate pretargeting into a clinical reality that could ideally fit into current theranostic and precision medicine perspectives. |
| first_indexed | 2024-12-16T09:58:27Z |
| format | Article |
| id | doaj.art-d8551b493b254c6699eda614f4cadf5d |
| institution | Directory Open Access Journal |
| issn | 2365-421X |
| language | English |
| last_indexed | 2024-12-16T09:58:27Z |
| publishDate | 2017-06-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | EJNMMI Radiopharmacy and Chemistry |
| spelling | doaj.art-d8551b493b254c6699eda614f4cadf5d2022-12-21T22:35:51ZengSpringerOpenEJNMMI Radiopharmacy and Chemistry2365-421X2017-06-012111410.1186/s41181-017-0026-8Pretargeting for imaging and therapy in oncological nuclear medicineClément Bailly0Caroline Bodet-Milin1Caroline Rousseau2Alain Faivre-Chauvet3Françoise Kraeber-Bodéré4Jacques Barbet5Service de Médecine Nucléaire, CHU de NantesService de Médecine Nucléaire, CHU de NantesService de Médecine Nucléaire, Institut de Cancérologie de l’OuestService de Médecine Nucléaire, CHU de NantesService de Médecine Nucléaire, CHU de NantesUniversité de NantesAbstract Background Oncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achieved market approval even though it could be considered the ultimate theranostic, combining PET imaging with short-lived positron emitters and therapy with radionuclides emitting beta or alpha particles. Results We have reviewed the pretargeting approaches proposed over the years, discussing their suitability for imaging, particularly PET imaging, and therapy, as well as their limitations. The reviewed pretargeting modalities are the avidin-biotin system, bispecific anti-tumour x anti-hapten antibodies and bivalent haptens, antibody-oligonucleotide conjugates and radiolabelled complementary oligonucleotides, and approaches using click chemistry. Finally, we discuss recent developments, such as the use of small binding proteins for pretargeting that may offer new perspectives to cancer pretargeting. Conclusions While pretargeting has shown promise and demonstrated preclinical and clinical proof of principle, full-scale clinical development programs are needed to translate pretargeting into a clinical reality that could ideally fit into current theranostic and precision medicine perspectives.http://link.springer.com/article/10.1186/s41181-017-0026-8PretargetingImmunoscintigraphyImmunoPETRadioimmunotherapyBispecific antibodyAvidin-biotin |
| spellingShingle | Clément Bailly Caroline Bodet-Milin Caroline Rousseau Alain Faivre-Chauvet Françoise Kraeber-Bodéré Jacques Barbet Pretargeting for imaging and therapy in oncological nuclear medicine EJNMMI Radiopharmacy and Chemistry Pretargeting Immunoscintigraphy ImmunoPET Radioimmunotherapy Bispecific antibody Avidin-biotin |
| title | Pretargeting for imaging and therapy in oncological nuclear medicine |
| title_full | Pretargeting for imaging and therapy in oncological nuclear medicine |
| title_fullStr | Pretargeting for imaging and therapy in oncological nuclear medicine |
| title_full_unstemmed | Pretargeting for imaging and therapy in oncological nuclear medicine |
| title_short | Pretargeting for imaging and therapy in oncological nuclear medicine |
| title_sort | pretargeting for imaging and therapy in oncological nuclear medicine |
| topic | Pretargeting Immunoscintigraphy ImmunoPET Radioimmunotherapy Bispecific antibody Avidin-biotin |
| url | http://link.springer.com/article/10.1186/s41181-017-0026-8 |
| work_keys_str_mv | AT clementbailly pretargetingforimagingandtherapyinoncologicalnuclearmedicine AT carolinebodetmilin pretargetingforimagingandtherapyinoncologicalnuclearmedicine AT carolinerousseau pretargetingforimagingandtherapyinoncologicalnuclearmedicine AT alainfaivrechauvet pretargetingforimagingandtherapyinoncologicalnuclearmedicine AT francoisekraeberbodere pretargetingforimagingandtherapyinoncologicalnuclearmedicine AT jacquesbarbet pretargetingforimagingandtherapyinoncologicalnuclearmedicine |